This article was written by Follow David A. Johnson is founder and principal of Endurance Capital Management, a New Jersey Limited Liability Company. As...
This article was written by Follow Nick Ackerman is a former financial advisor using his experience to provide coverage on closed-end funds and exchange-traded...
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is developing JNJ-2113 (PN-235), an oral IL-23 drug targeting psoriasis, however partner Johnson & Johnson (JNJ) says that until the...
The Biden administration has so far approved over $22 billion in student loan forgiveness for borrowers who were harmed by school misconduct. And the...